Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Casdozokitug · CHS-388, SRF-388

Monoclonal antibody · Antagonist of Interleukin-27 p28 subunit (IL-27p28) (IL27) · developed by Coherus Oncology

Phase 2 Most advanced trial

CHRS Developer

2 Registered trials

What is Casdozokitug?

Casdozokitug is a fully human IgG1 monoclonal antibody that binds the p28 subunit of the immunosuppressive cytokine IL-27, blocking its interaction with IL-27RA and the downstream STAT1 signaling. It is being studied in advanced solid tumors, clear cell renal cell carcinoma, hepatocellular carcinoma and non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: CHS-388, SRF-388
Drug type: Monoclonal antibody
Targets: Interleukin-27 p28 subunit (IL-27p28) (IL27)
Mechanism: Antagonist of Interleukin-27 p28 subunit (IL-27p28) (IL27)
Pathways: JAK-STAT signaling, STAT1 phosphorylation, IFN-gamma and TNF-alpha secretion, PD-L1, TIGIT and LAG3 expression
Therapy area: Oncology
Developer: Coherus Oncology, Inc. (CHRS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: AL6I5N2HTN

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06679985	Phase 2	Hepatocellular Carcinoma	Active not recruiting	CHRS
NCT04374877	Phase 1	Advanced Solid Tumor	Completed	CHRS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorClear Cell Renal Cell CarcinomaHepatocellular CarcinomaNon-small Cell Lung Cancer

More from Coherus Oncology

Toripalimab FDA approved CHS-0214 Phase 3 CHS-1000 Phase 1 Perenostobart Phase 2 Tagmokitug Phase 1

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the CHRS page.

Follow CHRS, the company behind Casdozokitug

See CHRS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CHRS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z